Business

Mass Movers

Ironwood suffers a ratings downgrade

Ironwood Pharmaceuticals is based in Cambridge.

David L. Ryan/Globe Staff/File 2012

Ironwood Pharmaceuticals is based in Cambridge.

Advertisement

Ironwood Pharmaceuticals said sales of its new constipation drug Linzess totaled $19.2 million in the fourth quarter, though that was not enough to offset higher costs. Ironwood lost $43.9 million, or 41 cents per share, as sales and administrative costs more than doubled to $33.3 million. A year earlier the company took a loss of $7 million, or 7 cents per share. An analyst at UBS downgraded the stock to “sell,” saying expectations for it are too high, and set an $11.50 price target.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com